Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 9:29 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 553–576 of 643 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Lacrimal Apparatus Disease Clear all
Recruiting Phase 2 Interventional

An Eight-Week Study to Evaluate the Safety and Efficacy of VSJ-110 Compared to Placebo in the Treatment of Dry Eye

NCT07179055
View directory record Official record
Conditions
Dry Eye
Interventions
VSJ-110, Placebo
Drug
Lead sponsor
Vanda Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
5
States / cities
Newport Beach, California • Andover, Massachusetts • Shelby, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2025 · Synced Oct 16, 2026, 9:29 AM EDT
Completed Not applicable Interventional Results available

e-Mobile Tablet for People With Chronic Conditions

NCT02833311
View directory record Official record
Conditions
Fibromyalgia, Multiple Sclerosis, Osteoarthritis, Sjögren's Syndrome, Parkinson's Disease
Interventions
Computer Tablet Group, Paper and Pencil Group, Contact Control Group
Behavioral
Lead sponsor
Case Western Reserve University
Other
Eligibility
18 Years to 76 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 12, 2023 · Synced Oct 16, 2026, 9:29 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Lifitegrast 5% Ophthalmic Solution and Contact Lens Dryness

NCT03686878
View directory record Official record
Conditions
Contact Lens, Contact Lens Discomfort, Contact Lens Dryness
Interventions
Lifitegrast
Drug
Lead sponsor
EV Clinical Trials
Other
Eligibility
21 Years and older
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Richardson, Texas
Source: ClinicalTrials.gov public record
Updated Sep 28, 2018 · Synced Oct 16, 2026, 9:29 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Investigator Initiated Study to Assess the Efficacy of OC-01 (Varenicline) Nasal Spray on Signs and Symptoms of Dry Eye Disease Following Laser-assisted in Situ Keratomileusis (LASIK)

NCT05082974
View directory record Official record
Conditions
Dry Eye Disease
Interventions
OC-01 (varenicline 0.6mg/ml) nasal spray, Placebo (vehicle) nasal spray
Drug
Lead sponsor
Vance Thompson Vision ND
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
West Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Jun 12, 2023 · Synced Oct 16, 2026, 9:29 AM EDT
Terminated Not applicable Interventional

Omega-3 Fatty Acid Supplements and Dry Eye

NCT01213342
View directory record Official record
Conditions
Keratoconjunctivitis Sicca
Interventions
Omega-3 Fatty Acid, Soybean Soft Gels
Dietary Supplement
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 20, 2012 · Synced Oct 16, 2026, 9:29 AM EDT
Terminated Phase 4 Interventional Results available

The Prophylactic Use of Topical Cyclosporine A 0.05% to Prevent Graft Versus Host Disease Related Dry Eye

NCT00553735
View directory record Official record
Conditions
Dry Eye
Interventions
Cyclosporine A 0.05%, Arificial Tear
Drug
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 28, 2017 · Synced Oct 16, 2026, 9:29 AM EDT
Terminated Not applicable Interventional

Evaluation of Tangible Boost for Patients With Stevens Johnson Syndrome, Sjogren's Syndrome, and Graft Vs Host Disease

NCT04313725
View directory record Official record
Conditions
Stevens-Johnson Syndrome, Graft Versus Host Disease in Eye, Sjogren's Syndrome, Dry Eye
Interventions
Tangible Boost, Placebo
Device · Other
Lead sponsor
Tangible Science
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Needham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 16, 2025 · Synced Oct 16, 2026, 9:29 AM EDT
Completed Not applicable Interventional Results available

iLux Treatment for Meibomian Gland Dysfunction (MGD)

NCT03055650
View directory record Official record
Conditions
Evaporative Dry Eye
Interventions
iLux 2020 System
Device
Lead sponsor
Tear Film Innovations, Inc.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
3
States / cities
Encinitas, California • San Diego, California
Source: ClinicalTrials.gov public record
Updated Nov 12, 2020 · Synced Oct 16, 2026, 9:29 AM EDT
Completed Not applicable Interventional Results available

The Efficacy of an Ocular Emulsion in Meibomian Gland Dysfunction

NCT01207752
View directory record Official record
Conditions
Meibomian Gland Dysfunction
Interventions
Systane Balance, Optive Lubricant Eye Drops
Drug
Lead sponsor
Southern California College of Optometry at Marshall B. Ketchum University
Other
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Fullerton, California
Source: ClinicalTrials.gov public record
Updated Apr 1, 2025 · Synced Oct 16, 2026, 9:29 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Clinical Evaluation of the InflammaDry Device for Detecting Dry Eye

NCT01692964
View directory record Official record
Conditions
Dysfunctional Tear Syndrome
Interventions
InflammaDry
Device
Lead sponsor
Rapid Pathogen Screening
Industry
Eligibility
18 Years and older
Enrollment
237 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
4
States / cities
Bradenton, Florida • Springfield, Missouri • Johnson City, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2020 · Synced Oct 16, 2026, 9:29 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

An Open-Label, Multi-Center, Clinical Study Evaluating the Effect of the NDE L68 StableFit® Punctal Plug on the Tear Lake

NCT04280653
View directory record Official record
Conditions
Dry Eye Syndromes
Interventions
NDE L68 StableFit® Punctal Plug
Device
Lead sponsor
Mati Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
2
States / cities
Edgewood, Kentucky • Garden City, New York
Source: ClinicalTrials.gov public record
Updated Dec 8, 2020 · Synced Oct 16, 2026, 9:29 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effects of Dry Eye Treatments on the Ocular Surface

NCT01797822
View directory record Official record
Conditions
Keratoconjunctivitis Sicca, Dry Eye Syndrome
Interventions
Dexamethasone, Artificial tear
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 5, 2020 · Synced Oct 16, 2026, 9:29 AM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Clinical Efficacy of Two Topical Dry Eye Drops for Central Corneal Stain Clearing Over 90 Days

NCT04172961
View directory record Official record
Conditions
Dry Eye
Interventions
nanomicellular cyclosporine 0.09%, Lifitegrast
Drug
Lead sponsor
Toyos Clinic
Other
Eligibility
18 Years to 85 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 20, 2022 · Synced Oct 16, 2026, 9:29 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate Safety and Efficacy of rhNGF Eye Solution vs Vehicle in Patients With Moderate to Severe Dry Eye

NCT03982368
View directory record Official record
Conditions
Dry Eye Syndrome
Interventions
rhNGF 20 μg/ml, rhNGF 20 μg/ml + vehicle, Vehicle
Drug · Other
Lead sponsor
Dompé Farmaceutici S.p.A
Industry
Eligibility
18 Years to 85 Years
Enrollment
261 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
12
States / cities
Glendale, California • Newport Beach, California • Rancho Cordova, California + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2024 · Synced Oct 16, 2026, 9:29 AM EDT
Completed Phase 2 Interventional Results available

Clinical Trial to Evaluate the Efficacy of OC-02 Nasal Spray on Signs and Symptoms of Dry Eye Disease (The PEARL Study)

NCT03452397
View directory record Official record
Conditions
Dry Eye Disease
Interventions
0.2 % hemigalactarate (0.11% free base) 0.2 % OC-02 Low Dose (1.1 mg/mL), 1.0 % hemigalactarate (0.11% free base) 1.0 % OC-02 Mid Dose (5.5 mg/mL), 2.0 % hemigalactarate (0.11% free base) 2.0 % OC-02 High Dose (11.1 mg/mL), Placebo (vehicle) nasal spray
Drug
Lead sponsor
Oyster Point Pharma, Inc.
Industry
Eligibility
22 Years and older
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
3
States / cities
Louisville, Kentucky • Andover, Massachusetts • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 14, 2021 · Synced Oct 16, 2026, 9:29 AM EDT
Completed Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-severe Systemic Disease Activity

NCT06104124
View directory record Official record
Conditions
Sjogren's Syndrome
Interventions
Dazodalibep, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
651 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
37
States / cities
Avondale, Arizona • Chandler, Arizona • Flagstaff, Arizona + 34 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 16, 2026, 9:29 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Dry Eye Disease Study With Brimonidine

NCT03418727
View directory record Official record
Conditions
Dry Eye
Interventions
Brimonidine, Brimonidine Mono Therapy, sodium carboxymethylcellulose, Corticosteroid Eye Drop
Drug
Lead sponsor
Ocugen
Industry
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
3
States / cities
Hoffman Estates, Illinois • Yorkville, Illinois • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 6, 2022 · Synced Oct 16, 2026, 9:29 AM EDT
Completed No phase listed Observational

Prospective Maternal Surveillance of SSA (Sjögren Syndrome A) Positive Pregnancies Using a Hand-held Fetal Heart Rate Monitor

NCT02920346
View directory record Official record
Conditions
Sjogren's Syndrome, Neonatal Systemic Lupus Erythematosus, Fetal Heart Block Complete
Interventions
Not listed
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 23, 2021 · Synced Oct 16, 2026, 9:29 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Diurnal Variation in Tear Osmolarity

NCT01321424
View directory record Official record
Conditions
Dry Eye Disease
Interventions
Not listed
Lead sponsor
Ophthalmic Consultants of Long Island
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2016
U.S. locations
6
States / cities
Fairfield, Connecticut • Lynbrook, New York • Manhasset, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2016 · Synced Oct 16, 2026, 9:29 AM EDT
Completed Not applicable Interventional Results available

Six Month Study to Evaluate the Safety and Effectiveness of the Intranasal Lacrimal Neurostimulator

NCT02526290
View directory record Official record
Conditions
Dry Eye Syndromes, Keratoconjunctivitis Sicca
Interventions
Intranasal Lacrimal Neurostimulator (Oculeve)
Device
Lead sponsor
Oculeve, Inc.
Industry
Eligibility
22 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
3
States / cities
Phoenix, Arizona • Andover, Massachusetts • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 31, 2017 · Synced Oct 16, 2026, 9:29 AM EDT
Terminated Phase 2 Interventional Results available

Pilot Study of a Homeopathic Therapy in Combination With Cyclosporin (Restasis) in the Treatment of Dry Eye Disease

NCT01072526
View directory record Official record
Conditions
Dry Eye Syndromes
Interventions
Euphrasia-based homeopathic therapy, Cyclosporin solution
Drug
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
21 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Oct 16, 2026, 9:29 AM EDT
Terminated Early Phase 1 Interventional

COVID-19 Vaccination in Rheumatic Disease Patients

NCT04839315
View directory record Official record
Conditions
Systemic Lupus Erythematosus, Sjogren's Syndrome, Inflammatory Myositis, Psoriatic Arthritis, Gout, Ankylosing Spondylitis, Arthritis of Multiple Sites Associated With Inflammatory Bowel Disease (Diagnosis), Osteoarthritis
Interventions
mRNA COVD19 vaccine
Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 3, 2022 · Synced Oct 16, 2026, 9:29 AM EDT
Completed No phase listed Observational

Evaluating Patients With Eye Allergies and Determining if There Are Also Dry Eyes

NCT01679015
View directory record Official record
Conditions
Dry Eyes, Allergic Conjunctivitis
Interventions
Not listed
Lead sponsor
Schwartz Laser Eye Center
Other
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 3, 2016 · Synced Oct 16, 2026, 9:29 AM EDT
Completed Phase 1Phase 2 Interventional

An Evaluation of the Impact of a Single Dose of P-552 on Oral Mucosal Wetness

NCT01369589
View directory record Official record
Conditions
Xerostomia, Sjogren's Syndrome
Interventions
P-552, Placebo
Drug
Lead sponsor
Parion Sciences
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 23, 2019 · Synced Oct 16, 2026, 9:29 AM EDT